An Open-label, Phase II Study to Evaluate the Clinical Efficacy and Safety of Tapinarof for Adult Patients With Palmoplantar Keratoderma
Latest Information Update: 26 Dec 2024
At a glance
- Drugs Tapinarof (Primary)
- Indications Palmoplantar keratoderma
- Focus Therapeutic Use
Most Recent Events
- 20 Dec 2024 Planned End Date changed from 1 Feb 2026 to 1 Nov 2026.
- 19 Sep 2024 Planned initiation date changed from 26 Aug 2024 to 26 Oct 2024.
- 23 Aug 2024 New trial record